NASDAQ: PROF TSX: PRN Certain statements in this presentation may contain certain information that is "forward-looking information" or "forward-looking statements" within the meaning of applicable securities laws with respect to Profound Medical Corp. ("Profound" or the "Company"). Such statements include all statements other than statements of historical fact contained in this presentation, such as statements that relate to the Company's current expectations and views of future events. Often, but not alway ...

EXHIBIT 99.1 G&A expenses for the 2022 fourth quarter decreased by 35% to approximately $2.1 million, compared with approximately $3.2 million in the same period in 2021, due to lower salaries and benefits, consulting fees, share based compensation, rent, software, insurance and other expenses. Fourth quarter 2022 S&D expenses decreased by 27% to approximately $1.7 million, compared with $2.3 million in the fourth quarter of 2021. This was driven by lower salaries and benefits, consulting fees and share bas ...

Profound Medical Corp. (NASDAQ:PROF) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Stephen Kilmer - IR Dr. Arun Menawat - CEO Rashed Dewan - CFO Conference Call Participants Michael Sarcone - Jefferies Rahul Sarugaser - Raymond James Brian Gagnon - Gagnon Securities Operator Good day, and thank you for standing by. Welcome to the Profound Medical Incorporated Third Quarter 2022 Conference Call. [Operator Instructions] Please be advised that today's conference is being reco ...

Profound Medical Corp. (NASDAQ:PROF) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Stephen Kilmer - IR Dr. Arun Menawat - CEO Rashed Dewan - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Zach Weiner - Jefferies Rahul Sarugaser - Raymond James Operator Welcome to the Profound Medical Second Quarter 2022 Financial Results Conference Call. My name is Darryl, and IÂ'll be your operator for todayÂ's call. [Operator Instructions] I will now turn the ...

Profound Medical Corp. (NASDAQ:PROF) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Dr. Arun Menawat – Chief Executive Officer and Chairman of the Board Rashed Dewan – Chief Financial Officer Stephen Kilmer – Investor Relations Conference Call Participants Rahul Sarugaser – Raymond James Frank Takkinen – Lake Street Capital Markets Josh Jeggings – Cowen and Company Scott McAuley – Paradigm Capital Brian Gagnon – Gagnon Securities Operator Good day, and thank you for standing by ...

Profound Medical Corp. (NASDAQ:PROF) Q4 2021 Results Conference Call March 3, 2022 4:30 PM ET Company Participants Stephen Kilmer - IR Dr. Arun Menawat - CEO Rashed Dewan - CFO Conference Call Participants Rahul Sarugaser - Raymond James Josh Jennings - Cowen Frank Takkinen - Lake Street Capital Brian Gagnon - Gagnon Securities Ben Haynor - Alliance Global Partners Operator Hello. Thank you for standing by. Welcome to the Profound Medical Q4 and Full Year 2021 Financial Results Conference Call. At this time ...

EXHIBIT 99.1 Profound Medical Announces Fourth Quarter and Full Year 2021 Financial Results TORONTO, March 03, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2021. Unless specified otherwise, all amounts in this press release ...

Financial Data and Key Metrics Changes - For Q3 2021, the company recorded revenue of $2.5 million, up 13% from $2.2 million in Q3 2020 [13] - Total operating expenses increased by 30% to $8.6 million compared to approximately $6.6 million in Q3 2020 [13] - The net loss for Q3 2021 was $6 million or $0.29 per share, compared to a net loss of $6.1 million or $0.33 per share in the same period of 2020 [15] Business Line Data and Key Metrics Changes - R&D expenses increased by 14% year-over-year to $4 million, driven by costs associated with clinical trials and MRI utilization [14] - G&A expenses rose by 35% to $2.5 million due to employee options and increased insurance costs [15] - Selling and distribution expenses surged by 72% to approximately $2 million [15] Market Data and Key Metrics Changes - TULSA-PRO procedure volumes in the U.S. grew 20% sequentially from Q2 to Q3 2021, indicating a developing trend [17] - The company expects to have approximately 20 U.S. installed sites by year-end, down from a previous estimate of 25 due to COVID-related delays [22] Company Strategy and Development Direction - The company is focusing on building a high-quality U.S. installed base by targeting early adopters, independent imaging centers, and leading teaching hospitals [19] - The strategy includes optimizing the onboarding process to reduce installation times post-pandemic [23] - The company is progressing with its reimbursement strategy, planning to file for a CPT code application in 2022 [30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term growth potential despite COVID-related challenges, citing strong utilization trends [18] - The company anticipates that delays in installations will diminish by year-end, allowing for a more robust growth trajectory in 2022 [23] - Management highlighted the importance of clinical data in supporting reimbursement applications and driving adoption [30] Other Important Information - The company has received FDA approval under Humanitarian Device Exemption for the treatment of osteoid osteoma, marking a significant milestone [8] - The interim results of a European trial showed superior outcomes for TULSA-PRO compared to traditional robotic prostatectomy [26] Q&A Session Summary Question: Update on the TACT trial - The TACT trial is nearing completion, with a few patients left to enroll, and three-year data shows continued improvement in side effects [34] Question: Install base expectations - There has been no dropout from the install base, and utilization continues to increase despite delays [39] Question: Impact of staffing shortages on procedure volumes - Staffing shortages have affected large hospitals, but the company has still seen significant growth in procedure volumes [41] Question: Capacity for installations in 2022 - The company has sufficient personnel to install devices rapidly, but hospital capacity remains a bottleneck [46] Question: Reimbursement timelines - The company plans to file for CPT-1 application next year, with all necessary clinical publications expected by the end of this year [50] Question: Trends in BPH versus cancer patients - The majority of patients treated are prostate cancer patients, with plans to broaden the scope for BPH applications in the future [92]

Profound Medical Corp. (NASDAQ:PROF) Q2 2021 Earnings Conference Call August 4, 2021 4:30 PM ET Company Participants Stephen Kilmer - Investor Relations Dr. Arun Menawat - Chief Executive Officer Aaron Davidson - Senior Vice President, Corporate Development Conference Call Participants Rahul Sarugaser - Raymond James Neil Chatterji - Cowen Anthony Petrone - Jefferies Frank Takkinen - Lake Street Capital Markets Ben Haynor - Alliance Global Partners Scott McAuley - Paradigm Capital Operator Good day and than ...

Financial Data and Key Metrics Changes - For Q1 2021, the company recorded revenue of $711,000, down 41% from $1.2 million in Q1 2020, marking the first revenue decline since Q1 2018 [11][15] - Total operating expenses increased by 47% to $6.8 million compared to approximately $2.1 million in Q1 2020 [13] - The company reported a net loss of $7.5 million or $0.37 per common share, compared to a net loss of $2.6 million or $0.21 per common share for the same period in 2020 [15] Business Line Data and Key Metrics Changes - The company is commercializing two main technologies: TULSA-PRO for prostate treatment and Sonalleve for uterine fibroids and palliative pain treatment [5][6] - TULSA-PRO sites have exceeded initial procedure targets, achieving an average run rate of 60 procedures per year, which is 50% higher than the initial estimate [20] Market Data and Key Metrics Changes - The U.S. market entry strategy for TULSA-PRO targets early adopters, independent imaging centers, and teaching hospitals, with agreements signed with top-tier hospitals across major markets [19][22] - The first quarter saw the best performance in terms of new TULSA-PRO system agreements signed, with expectations to go live in summer 2021 [23][26] Company Strategy and Development Direction - The company aims to regain momentum despite COVID-19 impacts, with a focus on increasing the installed base and procedure volumes [33][34] - The strategy includes pursuing a CPT-1 application to enhance reimbursement prospects, with plans to file by the end of 2022 [30][62] Management's Comments on Operating Environment and Future Outlook - Management remains cautious but optimistic about recovering Q1 revenue shortfalls throughout the remainder of 2021, citing positive trends in March and April [12][33] - The company is confident in the long-term adoption of TULSA-PRO, supported by agreements with leading hospitals and ongoing clinical studies [24][34] Other Important Information - The company has transitioned its presentation currency from Canadian dollars to U.S. dollars to streamline reporting [10] - Cash reserves as of March 31, 2021, were reported at $78.5 million [15] Q&A Session Summary Question: When do you expect the newly contracted sites to be operational? - Most sites are expected to be operational by the end of June or July, with some in Q4 [38] Question: How many systems will be installed in the initial 10 centers across Florida, Texas, and Pennsylvania? - Majority of systems will be in Florida, with at least half in that state and the rest in Texas and Pennsylvania [40] Question: What is the mix of procedures being performed? - Approximately 20% of patients treated are in the BPH category, with a variety of cancer stages being treated [41][42] Question: Can you provide visibility on the number of installations expected in Q2 and Q3? - The company expects to install at least one to two systems per month, aiming for a total of 75 installations by the end of the year [50] Question: What is the status of the C-Code and CPT-1 application? - The C-Code strategy is working well, with hospitals getting paid for procedures, and the CPT-1 application is expected to be filed in early 2022 [61][62]